Abstract
Background Test-negative design (TND) studies are increasingly common in evaluating vaccine effectiveness (VE) for various infectious diseases. TND studies are susceptible to bias due to disease outcome misclassification caused by imperfect test sensitivity and specificity. Several bias correction methods have been proposed. However, sample size or power considerations for TND studies incorporating bias correction for such misclassification have not yet been investigated. Methods Motivated by the world first malaria vaccine, we investigated how bias correction influences statistical power and sample size for VE estimation using Monte Carlo simulations. Under realistic assumptions about the proportion of vaccinated individuals in the general population, VE against clinical cases, and the probability of malaria diagnosis in unvaccinated individuals, we estimated the power to detect VE across different malaria vaccination statuses, with and without bias correction, at diagnostic test sensitivities of 60%, 80%, and 95%, and a specificity of 98%. Results The results demonstrated that using imperfect diagnostic tests reduces statistical power in both observed data-based VE and bias-corrected VE. The magnitude of power loss was substantially influenced by the sensitivity of the tests. Conclusions During the design phase of a TND study, researchers should conduct power calculations accounting for correcting the bias due to outcome misclassification. To achieve this, researchers need to collect comprehensive data, including the expected effect size of VE, the sensitivity and specificity of the diagnostic tests, the proportion of the vaccinated group, and the case ratio of the target disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
